Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS: We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS: For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“Any grade 3 or 4 adverse event 19 (25) 33 (44) 8 (11) 4 (6)”
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“Increase in aspartate aminotransferase 5 (7) 2 (3) — —”
BackgroundSelf-citationGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614 · cited 1×
“Decrease in neutrophil count 1 (1) 6 (8) 1 (1) 1 (1)”
Self-citationSabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V., Hocker, J. D., Dougherty, S., Qin, H., Klebanoff, C. A., Fry, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683847 · Cited by 383
Cited by
Items 701–800 of 1,024
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Zhang, Y., Li, C., Du, M., Jiang, H., Luo, W., Tang, L., Kang, Y. J., Xu, J. L., Wu, Z., Wang, X., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00822-w · Cited by 93
Self-citationRecent Advances in CAR-Based Solid Tumor Immunotherapy
Shin, M. H., Oh, E., Kim, Y. J., Nam, D.-H., Jeon, S., Yu, J. H., & Minn, D. (2023) · Cells · doi:10.3390/cells12121606 · Cited by 94
Lin, F. Y. H., Stuckert, A. J., Tat, C. L., White, M., Ruggieri, L., Zhang, H., Mehta, B., Lapteva, N., Mei, Z., Major, A. M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02019 · Cited by 97
Pui, C., Rebora, P., Schrappe, M., Attarbaschi, A., Baruchel, A., Basso, G., Cavé, H., Elitzur, S., Koh, K., Liu, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00822 · Cited by 86
“X,+1,+5,+6,+8,+9,+10,+11,+14,+15,+17,+18,+19, +20,+21,+22[5]/76,idemx2[30] LH”
Self-citationGenome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Shankar, K., Capitini, C. M., & Saha, K. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01741-4 · Cited by 85
Schalck, A., Sakellariou-Thompson, D., Forget, M.-A., Sei, E., Hughes, T. G., Reuben, A., Bai, S., Hu, M., Kumar, T., Hurd, M. W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1248 · Cited by 85
Nie, Y., Lu, W., Chen, D., Tu, H., Guo, Z., Zhou, X., Li, M., Tu, S., & Li, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00197-1 · Cited by 89
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Zhang, C., Wang, X., Zhang, R., Liu, F., Wang, Y., Yan, Z., Song, Y., Yang, T., Li, P., Wang, Z., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01056-6 · Cited by 90
Cox, M. J., Lucien, F., Sakemura, R. L., Boysen, J. C., Kim, Y., Horvei, P., Roman, C. M., Hansen, M. J., Tapper, E. E., Siegler, E. L., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.033 · Cited by 87
Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity
Foster, M. C., Savoldo, B., Lau, W., Rubiños, C., Grover, N. S., Armistead, P. M., Coghill, J. M., Hagan, R. S., Morrison, K., Buchanan, F. B., et al. (2021) · Blood · doi:10.1182/blood.2021010784 · Cited by 90
Zhang, H., Bu, C., Peng, Z., Li, G., Zhou, Z., Ding, W. Y., Zheng, Y., He, Y., Hu, Z., Pei, K., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01703-0 · Cited by 91
Enhancing CAR T-cell therapy through cellular imaging and radiotherapy
Minn, I., Rowe, S. P., & Pomper, M. G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30461-9 · Cited by 92
Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET
Simonetta, F., Alam, I. S., Lohmeyer, J. K., Sahaf, B., Good, Z., Chen, W., Xiao, Z., Hirai, T., Scheller, L., Engels, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2770 · Cited by 89
“Some studies have reported an association between 84 the peak and the duration of circulating CAR T cell levels and the clinical outcome (3–7) while other 85 studies have failed to confirm these results (8,9) suggesting that such a measure might not accurately 86 reflect the actual biodistribution and persistence of t…”
ResultClinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
Watanabe, N., McKenna, M. K., Shaw, A. R., & Suzuki, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.023 · Cited by 89
“In addition, Maude et al.27 treated pediatric B-ALL patients with second-generation CD19 CAR-T cells (19BBz) and reported 81% (61/75) of this group had MRD-negative CR.”
BackgroundOpportunities and Challenges in Drug Development for Pediatric Cancers
Laetsch, T. W., DuBois, S. G., Bender, J. G., Macy, M. E., & Moreno, L. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0779 · Cited by 91
“The development of CAR-T cells has revolutionized outcome for children with B-cell acute lymphoblastic leukemia,(55) leading to the approval of tisagenlecleucel.”
BackgroundSelf-citationGut Microbiota Influence in Hematological Malignancies: From Genesis to Cure
Uribe‐Herranz, M., Klein-González, N., Rodríguez‐Lobato, L. G., Juan, M., & de Larrea, C. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031026 · Cited by 88
Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy
Tedesco, V. E., & Mohan, C. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001249 · Cited by 89
Johnsrud, A. J., Craig, J. K., Baird, J. H., Spiegel, J. Y., Muffly, L. S., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004716 · Cited by 91
“Prior lines of therapy, n median (range) 3 (2-12) 3 (2-4) 3 (2-12) .”
Hebbar, N., Epperly, R., Vaidya, A. B., Thanekar, U., Moore, S. E., Umeda, M., Ma, J., Patil, S. L., Langfitt, D. M., Huang, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28243-6 · Cited by 87
Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications
Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D., Vu‐Thi, H., Alzahrani, K. J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.005 · Cited by 96
Kampouri, E., Walti, C. S., Gauthier, J., & Hill, J. A. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2063833 · Cited by 94
“Several CD19-targeted CAR-T-cell products have now been approved by the US Food and Drug Administration (FDA) and include: tisagenlecleucel (Kymriah; Novartis) for R/R B-cell ALL and large B-cell lymphomas [1,2],”
BackgroundApproved CAR-T therapies have reproducible efficacy and safety in clinical practice
Vera, D. G., Waghela, H., Nuh, M., Pan, J. Z., & Lulla, P. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2378543 · Cited by 99
Wölfl, M., Rasche, M., Eyrich, M. K., Schmid, R., Reinhardt, D., & Schlegel, P. G. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018093 · Cited by 88
“Results and discussion CD19-directed immunotherapy, either antibody- or T-cell-based, has shown tremendous clinical success for patients with otherwise refractory CD19(1) B-cell leukemia.(12) For infant ALL, high relapse rates and poor outcome of patients with relapsed disease have been reported even with SCT frequent…”
BackgroundInflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
Fishman, J. A., Hogan, J. I., & Maus, M. V. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1025 · Cited by 86
“More severe CRES is observed in those with higher grades of CRS [58, 60].”
BackgroundLissandrello, C. A., Santos, J. A., Hsi, P., Welch, M., Mott, V. L., Kim, E. S., Chesin, J., Haroutunian, N. J., Stoddard, A. G., Czarnecki, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73755-0 · Cited by 82
Persson, M. L., Douglas, A. M., Alvaro, F., Faridi, P., Larsen, M. R., Alonso, M. M., Vitanza, N. A., & Dun, M. D. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac117 · Cited by 89
Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 98
“Since the approval of CD19-targeted CAR T cell therapy for patients with acute lymphoblastic leukemias (ALL), the indication has expanded to aggressive B cell lymphomas.”
InfluentialMechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
Dholaria, B., Bachmeier, C. A., & Locke, F. L. (2018) · BioDrugs · doi:10.1007/s40259-018-0324-z · Cited by 85
Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds
Zhang, D. K. Y., Cheung, A. S., & Mooney, D. J. (2020) · Nature Protocols · doi:10.1038/s41596-019-0249-0 · Cited by 88
Volpe, A., Lang, C., Lim, L., Man, F., Kurtys, E., Ashmore‐Harris, C., Johnson, P., Skourti, E., de Rosales, R. T. M., & Fruhwirth, G. O. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.028 · Cited by 85
“The ideal reporter for cell tracking applications in human settings is (1) detected with exquisite sensitivity using clinical imaging modalities, (2) does not elicit immunogenic reactions, (3) shows very limited endogenous expression and thus high specificity for traceable cells, (4) can be detected with a widely avai…”
BackgroundFan, F., Yoo, H. J., Stock, S., Wang, L., Liu, Y., Schubert, M., Wang, S., Neuber, B., Hückelhoven‐Krauss, A., Gern, U., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33212 · Cited by 90
CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function
Boucher, J. C., Li, G., Kotani, H., Cabral, M. L., Morrissey, D., Lee, S. B., Spitler, K., Beatty, N. J., Cervantes, E. V., Shrestha, B., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0253 · Cited by 87
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 94
“…cell surface [250] By combining these The world of clinical trials is abuzz with personalized cancer vaccines and neoantigen-targeting therapies [271,272]. innovative approaches, researchers have substantially improved the process of neoantigen selection, bolstering the potential Challenges…”
BackgroundDriving CAR T cell translation forward
Schultz, L. M., & Mackall, C. L. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2127 · Cited by 84
“The phase 2 study of tisagenlecleucel in pediatric ALL did not reveal differential CAR T cell expansion between responders and nonresponders, but persistence did correlate with sustained clinical responses (2).”
BackgroundInfluentialLeung, W., Gay, J. W., Martin, U., Garrett, T. E., Horton, H. M., Certo, M. T., Blazar, B. R., Morgan, R. A., Gregory, P. D., Jarjour, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124430 · Cited by 90
“Other less severe complications from CD19 CAR T cell therapy such as chronic B cell aplasia (3) and increased risk for infections (10) can be divided into short- and long-term effects.”
BackgroundByrne, M. T., Oluwole, O. O., Savani, B. N., Majhail, N. S., Hill, B. T., & Locke, F. L. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.036 · Cited by 81
“Further, none of the DLBCL patients were allog-rafted before enrollment (these patients were excluded from ZUMA-1 and JULIET), but the ALL literature indicates that CAR T cell therapy after allogeneic HCT is feasible and safe [37,42].”
BackgroundAdvanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Blache, U., Weiss, R., Boldt, A., Kapinsky, M., Blaudszun, A.-R., Quaiser, A., Pohl, A., Miloud, T., Burgaud, M., Vucinic, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658314 · Cited by 75
Highly Efficient Transfection of Human Primary T Lymphocytes Using Droplet-Enabled Mechanoporation
Joo, B., Hur, J., Kim, G.-B., Yun, S. G., & Chung, A. J. (2021) · ACS Nano · doi:10.1021/acsnano.0c10473 · Cited by 86
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring
Kantarjian, H. M., & Jabbour, E. J. (2025) · American Journal of Hematology · doi:10.1002/ajh.27708 · Cited by 100
Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., Sawada, N., Tsunoda, H., Shima, T., Miyawaki, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1216 · Cited by 80
The paths and challenges of “off-the-shelf” CAR-T cell therapy: an overview of clinical trials
Moradi, V., Omidkhoda, A., & Ahmadbeigi, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115888 · Cited by 80
Engineering CAR-T Cells for Improved Function Against Solid Tumors
Morgan, M. A., & Schambach, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02493 · Cited by 88
“Gammaretro- and lentiviral vectors as well as Sleeping Beauty transposon based vectors are frequently used for this purpose (7, 9, 15, 19, 90).”
BackgroundTargeting loss of heterozygosity for cancer-specific immunotherapy
Hwang, M. S., Mog, B. J., Douglass, J., Pearlman, A. H., Hsiue, E. H.-C., Paul, S., DiNapoli, S. R., Konig, M. F., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022410118 · Cited by 83
Wudhikarn, K., Flynn, J. R., Rivière, I., Gönen, M., Wang, X., Sénéchal, B., Curran, K. J., Roshal, M., Maslak, P. G., Geyer, M. B., et al. (2021) · Blood · doi:10.1182/blood.2020009515 · Cited by 85
CAR-T cell therapy for the treatment of adult high-grade gliomas
Park, S., Maus, M. V., & Choi, B. D. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00753-0 · Cited by 91
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
Long, K. B., Young, R. M., Boesteanu, A. C., Davis, M. M., Melenhorst, J. J., Lacey, S. F., DeGaramo, D. A., Levine, B. L., & Fraietta, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02740 · Cited by 78
Self-citationAn, F., Wang, H., Liu, Z., Wu, F., Zhang, J., Tao, Q., Li, Y., Shen, Y., Ruan, Y., Zhang, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19774-x · Cited by 87
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Bansal, D., Reimers, M. A., Knoche, E. M., & Pachynski, R. K. (2021) · Cancers · doi:10.3390/cancers13020334 · Cited by 85
“(F) 4-1BB stimulation has been employed extensively in chimeric antigen receptor (CAR) T cell therapies, and utomilumab, a monoclonal agonist antibody that binds to the 4-1BB is currently in clinical trials for patients with mCRPC. (G) Currently, there are four clinical trials combining adenosine receptor antagonists…”
BackgroundSystematic Review of Available CAR-T Cell Trials around the World
Barros, L. R. C., Couto, S. C. F., da Silva Santurio, D., Paixão, E. A., Cardoso, F., da Silva, V. J., Klinger, P., Ribeiro, P. D. A. C., Rós, F. A., Oliveira, T. G. M., et al. (2022) · Cancers · doi:10.3390/cancers14112667 · Cited by 76
“It is also noteworthy and expected that most trials are very recent, with outstanding growth after CAR-T approval for leukemia in 2017 [15].”
BackgroundHiltensperger, M., & Krackhardt, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121030 · Cited by 89
“This can result in reduced fitness or even manufacturing failure of the autologous CAR-T cell product (102, 103).”
BackgroundFratricide-resistant CD7-CAR T cells in T-ALL
Oh, B. L. Z., Shimasaki, N., Coustan‐Smith, E., Chan, E., Poon, L. M., Lee, S. H. R., Yeap, F., Tan, L. K., Chai, L. Y. A., Bert, N. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03228-8 · Cited by 91
Mahmoudjafari, Z., Hawks, K. G., Hsieh, A. A., Plesca, D. C., Gatwood, K. S., & Culos, K. A. A. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.024 · Cited by 80
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
Bachanová, V., Bishop, M. R., Dahi, P. B., Dholaria, B., Grupp, S. A., Hayes‐Lattin, B., Janakiram, M., Maziarz, R. T., McGuirk, J. P., Nastoupil, L. J., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.008 · Cited by 81
Self-citationNucleic Acid-Based Approaches for Tumor Therapy
Hager, S., Fittler, F. J., Wagner, E., & Bros, M. (2020) · Cells · doi:10.3390/cells9092061 · Cited by 81
“Of these, treatment with tisagenlecleucel (T cells from the patients’ blood are lentivirally transduced with CD19-speciic CARs) yielded an overall remission rate of 81% after three months in patients suffering from relapsed or refractory ALL, but caused serious, mainly reversible toxic effects in children and young ad…”
BackgroundCLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy
Willier, S. M., Rothämel, P., Hastreiter, M., Wilhelm, J., Stenger, D., Blaeschke, F., Rohlfs, M., Kaeuferle, T., Schmid, I., Albert, M. H., et al. (2020) · Blood · doi:10.1182/blood.2020006921 · Cited by 86
Frank, A. M., Braun, A. H., Scheib, L., Agarwal, S., Schneider, I. C., Fusil, F., Perian, S., Sahin, U., Thalheimer, F. B., Verhoeyen, E., et al. (2020) · PubMed Central · doi:10.1182/bloodadvances.2020002229 · Cited by 120
“Their potential has been further underscored by the recent approval of 2 CD19-specific chimeric antigen receptor (CAR) T-cell therapies for treatment of hematological diseases in Europe and the United States.(1,2) Several hundred clinical studies are ongoing assessing CAR T-cell therapies for various types of cancers…”
BackgroundQin, H., Yang, L., Chukinas, J. A., Shah, N. N., Tarun, S., Pouzolles, M., Chien, C. D., Niswander, L. M., Welch, A. R., Taylor, N. N., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003149 · Cited by 82
Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
Yang, L., Ning, Q., & Tang, S. (2022) · Journal of Immunology Research · doi:10.1155/2022/8052212 · Cited by 98
Sánchez‐Martínez, D., Tirado, N., Mensurado, S., Martínez‐Moreno, A., Romecín, P. A., Gutiérrez‐Agüera, F., Correia, D. V., Silva‐Santos, B., & Menéndez, P. R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005400 · Cited by 79
Cardiotoxicity of T-Cell Antineoplastic Therapies
Ganatra, S., Dani, S. S., Yang, E. H., Zaha, V. G., & Nohria, A. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.07.014 · Cited by 87
Wang, Y., Tong, C., Lu, Y., Wu, Z., Guo, Y., Liu, Y., Wei, J., Wang, C., Yang, Q., & Han, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01659-2 · Cited by 89
“9,10 13 Previously, we screened tandem CD19 and CD20 CAR-T cells (TanCAR7 T cells) and provided evidence of their ef fi cacy in the treatment of recurrent/refractory non-Hodgkin lymphoma (r/rNHL).”
BackgroundLymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
Dwivedi, A., Karulkar, A., Ghosh, S., Rafiq, A., & Purwar, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03180 · Cited by 85
Promises and challenges of a decentralized CAR T-cell manufacturing model
Shah, M., Krull, A., Odonnell, L., de Lima, M. J., & Bezerra, E. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1238535 · Cited by 77
CAR-Expressing Natural Killer Cells for Cancer Retargeting
Kloeß, S., Kretschmer, A., Stahl, L., Fricke, S., & Koehl, U. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000495771 · Cited by 81
Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy
Isser, A., Livingston, N. K., & Schneck, J. P. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120584 · Cited by 79
CD58 loss in tumor cells confers functional impairment of CAR T cells
Yan, X., Chen, D., Ma, X., Wang, Y., Guo, Y., Wei, J., Tong, C., Zhu, Q., Lu, Y., Yu, Y., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007891 · Cited by 79
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Nasiri, F., Kazemi, M., Mirarefin, S. M. J., Kancha, M. M., Najafabadi, M. A., Salem, F., Shokoohi, S. D., Bakhshi, S. E., Kozani, P. S., & Kozani, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018786 · Cited by 81
Graham, C., Velasco, R., Tomás, A. A., Stewart, O., Dachy, G., Bufalo, F. D., Doglio, M., Henter, J., Ortí, G., Perić, Z., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00715-0 · Cited by 87
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
Rosewell Shaw, A., & Suzuki, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02103 · Cited by 74
“(3) OV infection can induce expression of MHC-I and”
BackgroundTCR-like antibodies in cancer immunotherapy
He, Q., Liu, Z., Liu, Z., Lai, Y., Zhou, X., & Weng, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0788-4 · Cited by 84
CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice
Porcellini, S., Asperti, C., Corna, S., Cicoria, E., Valtolina, V., Stornaiuolo, A., Valentinis, B., Bordignon, C., & Traversari, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00099 · Cited by 81
“It is well known that clinical responses often correlate with CAR T cell expansion and persistence (1, 2).”
BackgroundResultTipanee, J., Samara-Kuko, E., Gevaert, T., Chuah, M. K., & VandenDriessche, T. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.006 · Cited by 76
Geyer, M. B., Rivière, I., Sénéchal, B., Wang, X., Wang, Y., Purdon, T. J., Hsu, M., Devlin, S. M., Halton, E. F., Lamanna, N., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.018 · Cited by 79
Schuster, S. J., Maziarz, R. T., Rusch, E. S., Li, J., Signorovitch, J., Romanov, V. V., Locke, F. L., & Maloney, D. G. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001304 · Cited by 82
Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
Mhaidly, R., & Verhoeyen, E. (2020) · Cancers · doi:10.3390/cancers12071915 · Cited by 79
“T cells modified for chimeric antigen receptor (CAR) expression that recognizes a specific antigen on the surface of malignant B cells, such as CD19, is one of the biggest steps forward in conquering cancer [16,19,31].”
BackgroundIntracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation
Raes, L., Stremersch, S., Fraire, J. C., Brans, T., Goetgeluk, G., Munter, S. D., Hoecke, L. V., Verbeke, R., Hoeck, J. V., Xiong, R., et al. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00523-0 · Cited by 86
“, KymriahTM (tisagenlecleucel; Novartis) [6] and YescartaTM (axicabtagene ciloleucel; Kite Pharma, Gilead) [7, 8], have been approved by the US Food and Drug Administration (FDA) [9, 10].”
BackgroundWang, Y., Wang, J., Yang, X., Yang, J., Lu, P., Zhao, L., Li, B., Pan, H., Jiang, Z., Shen, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.628906 · Cited by 90
“CAR T cell therapy has gained remarkable success in the clinical treatment of hematological malignancies (2, 3).”
BackgroundSchultz, L. M., Eaton, A. A., Baggott, C., Rossoff, J. E., Prabhu, S., Keating, A. K., Krupski, C., Pacenta, H. L., Phillips, C. L., Talano, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01076 · Cited by 79
Self-citationPan, J., Tang, K., Luo, Y., Seery, S., Tan, Y., Deng, B., Liu, F., Xu, X., Ling, Z., Song, W., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00436-9 · Cited by 81
Self-citationAbbott, R. C., Cross, R. S., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020515 · Cited by 84
“Two CD19 specific CAR T cell products were FDA approved in 2017, tisagenlecleucel (Kymriah) [23,24] for B cell precursor Acute Lymphoblastic Leukaemia (B-ALL) and axicabtagene ciloleucel (Yescarta) for large B cell lymphomas [25].”
BackgroundThe Biology of B-Progenitor Acute Lymphoblastic LeukemiaPreprint
Roberts, K. G., & Mullighan, C. G. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034835 · Cited by 76
“…new immunotherapeutic approaches including blinatumomab (CD19/CD3 bispecific T-cell engager), inotuzumab ozagamicin (anti- CD22 antibody conjugated to calicheamicin), and CAR T cells (chimeric antigen receptor) (Davila et al. 2014; Kantarjian et al. 2016, 2017; Maude et al. 2018; Park et al. 2018).”
BackgroundDavis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2164 · Cited by 75
Self-citationChimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
Cummins, K. D., & Gill, S. I. (2019) · Haematologica · doi:10.3324/haematol.2018.208751 · Cited by 75
“81% of patients, and event-free survival rates of 73% and 50% at six and 12 months, respectively.(1) A detailed summary of the design and basic biology of CAR”
BackgroundLocatelli, F., Zugmaier, G., Mergen, N., Bader, P., Jeha, S., Schlegel, P., Bourquin, J., Handgretinger, R., Brethon, B., Rössig, C., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005579 · Cited by 89
“Although excellent remission rates have been achieved using approved CAR T-cell therapies in the treatment of hematologic malignancies, they have been associated with very high incidences of CRS (42%-93%).(11,22-25) In this study, the CRS rates were very low compared with those observed with approved CAR T-cell therap…”
MethodResultSelf-citationA Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
Miao, L., Zhang, J., Zhang, Z., Wang, S., Tang, F., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840956 · Cited by 80
“The results showed that (50), the total remission rate of these patients was 81%; the 6-month and 12-month overall survival rate were 90% and 76%, respectively; 55 patients (73%) had a grade 3 or 4 tisagenlecleucel-related adverse event.”
BackgroundInfluentialRecent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Kozani, P. S., Kozani, P. S., Najafabadi, M. A., Yousefi, F., Mirarefin, S. M. J., & Rahbarizadeh, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795164 · Cited by 78
“It has not been a long time since the first CAR-T product (named tisagenlecleucel) received US Food and Drug Administration (FDA) approval in 2017 for medical use in clinics (25, 26).”
BackgroundKreatsoulas, D. C., Bolyard, C. M., Wu, B. X., Çam, H., Giglio, P., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01298-0 · Cited by 86
In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity
Gong, N., Han, X., Xue, L., El-Mayta, R. D., Metzloff, A. E., Billingsley, M. M., Hamilton, A. G., & Mitchell, M. J. (2023) · Nature Materials · doi:10.1038/s41563-023-01646-6 · Cited by 79
“However, neurotoxicity is usually delayed for weeks after the disappearance of CRS-related symptoms and may induce patient death 19,20 .”
BackgroundHill, J. A., Krantz, E. M., Hay, K. A., Dasgupta, S., Stevens‐Ayers, T., Ignacio, R. B., Bar, M., Maalouf, J., Cherian, S., Chen, X., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000717 · Cited by 78
Krishnamoorthy, S., Ghobadi, A., Santos, R. D., Schilling, J. D., Malone, A. F., Murad, H. F., Bartlett, N. L., & Alhamad, T. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16367 · Cited by 79
Saini, N. Y., Swoboda, D. M., Greenbaum, U., Ma, J., Patel, R. D., Devashish, K., Das, K., Tanner, M. R., Strati, P., Nair, R., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0177 · Cited by 74
Britten, O., Ragusa, D., Tosi, S., & Kamel, Y. M. (2019) · Cells · doi:10.3390/cells8111341 · Cited by 83
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity
Yu, X., Chan, H. T. C., Fisher, H., Penfold, C. A., Kim, J., Inzhelevskaya, T., Mockridge, C. I., French, R. R., Duriez, P. J., Douglas, L. R., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.013 · Cited by 80
“To further explore anti-CD40 mAb therapy for effective cancer treatment, we investigated the potentiating effect of 341G2 hIgG2 on adoptive T cell transfer that has demonstrated clinical efficacy in some difficult-to-treat cancers (Maude et al., 2018; Neelapu et al., 2017).”
BackgroundBeyond the storm — subacute toxicities and late effects in children receiving CAR T cells
Shalabi, H., Gust, J., Taraseviciute, A., Wolters, P. L., Leahy, A. B., Sandi, C., Laetsch, T. W., Wiener, L. S., Gardner, R. A., Nussenblatt, V. R., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00456-y · Cited by 80
Self-citationAnti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma
Supimon, K., Sangsuwannukul, T., Sujjitjoon, J., Phanthaphol, N., Chieochansin, T., Poungvarin, N., Wongkham, S., Junking, M., & Yenchitsomanus, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-85747-9 · Cited by 79
Little, J. S., Aleissa, M. M., Beluch, K., Gonzalez-Bocco, I. H., Marty, F. M., Manne‐Goehler, J., Koo, S., Hammond, S. P., & Jacobson, C. A. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007474 · Cited by 76
“Prior lines of chemotherapy, median (range) 3 (2-10)”
BackgroundNon-viral chimeric antigen receptor (CAR) T cells going viral
Balke‐Want, H., Keerthi, V., Cadiñanos-Garai, A., Fowler, C., Gkitsas-Long, N., Brown, A. K., Tunuguntla, R. H., Abou‐El‐Enein, M., & Feldman, S. A. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100375 · Cited by 90
Jung, I.-Y., Noguera-Ortega, E., Bartoszek, R. L., Collins, S. M., Williams, E. F., Suhoski, M. M., Jadlowsky, J. K., Plesa, G., Siegel, D. L., Chew, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101053 · Cited by 84
Self-citationFine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., & Zhou, D. (2023) · Cancers · doi:10.3390/cancers15133476 · Cited by 83
“In HER2-expressing cancer cells and mouse tumor models, the technique can precisely and efficiently kill cancer cells with elevated HER2 expression but spare normal cells with reduced HER2 expression.”
BackgroundResultInfluentialGraham, C., Lee, W., Wiggin, H. R., Supper, V. M., Leick, M. B., Birocchi, F., Yee, A. J., Petrichenko, A., Everett, J. K., Bushman, F. D., et al. (2023) · Blood · doi:10.1182/blood.2023021429 · Cited by 78
Metadata
- Authors
- Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Oslo University Hospital (NO)
- Hospital Sant Joan de Déu Barcelona (ES)
- University of Minnesota (US)
- Children's Mercy Hospital (US)
- From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia (S.L.M., S.A.G.) — all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern...
- Royal Children's Hospital (AU)
- University of Southern California (US)
- ORCID
- Maude, Shannon L.
- Laetsch, Theodore W.
- Buechner, Jochen
- Rives, Susana
- Boyer, Michael
- Bittencourt, Henrique
- Bader, Peter
- Verneris, Michael R.
- Stefanski, Heather E.
- Qayed, Muna
- Hiramatsu, Hidefumi
- Davis, Kara L.
- Martin, Paul L.
- Nemecek, Eneida R.
- Yanik, Gregory A.
- Peters, Christina
- Boissel, Nicolas
- Mechinaud, Francoise
- Balduzzi, Adriana
- Krueger, Joerg
- June, Carl H.
- Levine, Bruce L.
- Zhang, Yiyun
- Lebwohl, David
- Pulsipher, Michael A.
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 439-448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5996391
- OpenAlex
- W2787301955
- Cited by
- 5,735
- References
- 24
- Citations by year
- 2026: 573 · 2025: 671 · 2024: 734 · 2023: 730 · 2022: 784 · 2021: 788 · 2020: 706 · 2019: 496 · 2018: 242
- FWCI
- 207.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tisagenlecleucel, CAR T-cell therapy, anti-CD19, B-cell acute lymphoblastic leukemia, relapsed/refractory leukemia, pediatric and young adult patients, complete remission, minimal residual disease, event-free survival, overall survival, cytokine release syndrome, neurological adverse events, CAR T cell persistence, tocilizumab, treatment toxicity
- MeSH terms
- Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Female, Humans, Infusions, Intravenous, Male, Receptors, Antigen, T-Cell, Remission Induction, Survival Analysis, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.